September 25, 2016 6:56 PM ET


Company Overview of Dermira, Inc.

Company Overview

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company’s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which is in Phase III clinical trial for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and DRM01, a small-molecule sebum inhibitor, which is in Phase IIb clinical trial for the treatment of a...

275 Middlefield Road

Suite 150

Menlo Park, CA 94025

United States

Founded in 2010

62 Employees



Key Executives for Dermira, Inc.

Co-Founder, Chairman and Chief Executive Officer
Age: 64
Total Annual Compensation: $465.0K
Co-Founder, Chief Medical Officer, Director and Member of Science & Technology Committee
Age: 74
Total Annual Compensation: $350.0K
Chief Financial Officer and Chief Operating Officer
Age: 48
Total Annual Compensation: $355.0K
Chief Development Officer
Age: 54
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2015.

Dermira, Inc. Key Developments

Dermira, Inc. Licenses DRM04 to Maruho for Hyperhidrosis in Japan

Dermira, Inc. announced it has entered into an exclusive license agreement with Maruho Co. Ltd. Pursuant to the terms of the agreement, Dermira has granted Maruho an exclusive license to develop and commercialize DRM04, a topical anticholinergic product candidate currently being developed by Dermira for the treatment of primary axillary hyperhidrosis (excessive underarm sweating), in Japan. Under the terms of the agreement, Dermira will receive an initial $25 million license payment. Dermira also is eligible to receive potential additional payments totaling up to $70 million, contingent on the achievement of milestones associated with submission and approval of a marketing application and certain sales thresholds, as well as royalty payments representing up to a low double-digit percentage of net product sales, in Japan. Maruho is responsible for funding all development and commercial costs for the program in Japan. Until such time, if any, as Maruho elects to establish its own source of supply, Maruho will purchase product supply from Dermira for development and, if applicable, commercial purposes at cost. Subject to discussions with Japanese regulatory authorities, Maruho plans to initiate a Phase 1 clinical trial for DRM04 in Japan. This license agreement between Dermira and Maruho is not subject to the existing Right of First Negotiation Agreement entered into between the parties in 2013, in connection with which Maruho also made an investment in Dermira.

Dermira, Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months June 30, 2016

Dermira, Inc. reported consolidated earnings results for the second quarter and six months June 30, 2016. For the quarter, the company reported loss from operations of $28,041,000 against $17,343,000 a year ago. Net loss was $27,755,000 against $17,159,000 a year ago. Net loss per basic and diluted share was $0.89 against $0.69 a year ago. For the six months, the company loss from operations of $56,796,000 against $31,577,000 a year ago. Net loss was $56,191,000 against $31,194,000 a year ago. Net loss per basic and diluted share was $1.84 against $1.26 a year ago.

Dermira Mulls Acquisitions

Dermira, Inc. is lloking for acquisitions. The company which has offered 4.5 million common stocks, intends to use the net proceeds for expand business by in-licensing or acquiring, as the case may be, commercial products, product candidates, technologies, compounds, other assets or complementary businesses.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Dermira, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at